|

Liver Disease Clinical Trials in Connecticut

29 recruiting studies across 19 cities

All Trials in Connecticut

Phase
Trial Phase Location
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have CirrhosisPhase 3Bristol
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver FibrosisPhase 3Bristol
Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT TrialPhase 3Derby
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine TumorsPhase 2Derby
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)Phase 3Hamden
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry—Hartford
Integrated Cancer Repository for Cancer Research—Manchester
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid TumorsPhase 1New Haven
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and ChemotherapyPhase 3New Haven
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASHPhase 3New Haven
A Study of the Safety and Efficacy of Prime Editing (PM577) in Participants With Wilson Disease (WD)Phase 1/2New Haven
Digoxin In NASH (CODIN)Phase 2New Haven
Dissemination of the Donor Application: Utilizing Social Media to Identify Potential Live Organ DonorsN/ANew Haven
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 YearsPhase 4New Haven
Empagliflozin in Patients With Cirrhosis and AscitesPhase 2New Haven
FOG-001 in Locally Advanced or Metastatic Solid TumorsPhase 1/2New Haven
Implementation Facilitation Pilot for Alcohol Use Disorder (AUD) in Alcohol-associated Liver Disease (ALD)N/ANew Haven
Natural History of Wilson Disease—New Haven
Off Treatment Urinary Copper Excretion in Wilson Disease, Pilot Study—New Haven
Pathogenesis of Pediatric Nonalcoholic Fatty Liver Disease (NAFLD)—New Haven
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular CarcinomaPhase 3New Haven
Reversal of Lipid-Induced Insulin ResistanceN/ANew Haven
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid TumorsPhase 1New Haven
Study to Evaluate the Safety and Efficacy of Larsucosterol in Participants With Alcohol-associated Hepatitis (AH)Phase 3New Haven
The Dragon PLC Trial (DRAGON-PLC)N/ANew Haven
Trientine Tetrahydrochloride Administered Once a Day for the First Line Treatment of Wilson's Disease Patients.Phase 3New Haven
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF AlterationsPhase 2Norwalk
Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRIN/AWest Haven
Veteran-Centered Care for Advanced Liver Disease (Vet-CALD)N/AWest Haven

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.